The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with methadone.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with bepridil.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Dronedarone.


The serum concentration of the active metabolites of clarithromycin can be increased when clarithromycin is used in combination with Fosphenytoin.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with scopolamine.


The serum concentration of the active metabolites of Isavuconazonium can be increased when Isavuconazonium is used in combination with nelfinavir.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with dexamethasone.


The serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with clarithromycin.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Propoxyphene napsylate.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with hydroxyzine.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with nicardipine.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with clotrimazole.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with venlafaxine.


The serum concentration of the active metabolites of clarithromycin can be increased when clarithromycin is used in combination with Lumacaftor.


The serum concentration of the active metabolites of ifosfamide can be increased when ifosfamide is used in combination with phenobarbital.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Tramadol.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with tamoxifen.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with VERAPAMIL.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with mirtazapine.


The serum concentration of the active metabolites of floxuridine can be increased when floxuridine is used in combination with cimetidine.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with carvedilol.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with metoprolol.


The serum concentration of the active metabolites of Isavuconazonium can be increased when Isavuconazonium is used in combination with Voriconazole.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with buprenorphine.


The serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with ketoconazole.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with SIMEPREVIR.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Rolapitant.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Halofantrine.


The serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with itraconazole.


The serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with SAQUINAVIR.


The serum concentration of the active metabolites of Isavuconazonium can be increased when Isavuconazonium is used in combination with clarithromycin.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with lidocaine.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with mitomycin C.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Telmisartan.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with digoxin.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with felodipine.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Ziprasidone.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with ritonavir.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Gefitinib.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with trifluoperazine.


The serum concentration of the active metabolites of clarithromycin can be increased when clarithromycin is used in combination with nevirapine.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with terbinafine.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with mifepristone.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Telaprevir.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Imatinib.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with itraconazole.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Reboxetine.


The serum concentration of the active metabolites of RIFABUTIN can be increased when RIFABUTIN is used in combination with Darunavir.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with METHAMPHETAMINE.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with atenolol.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with amodiaquine.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with miconazole.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with mebendazole.


The serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Midostaurin.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with glyburide.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Daclatasvir.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with olanzapine.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with efavirenz.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with midodrine.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with FLUPHENAZINE.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Posaconazole.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with lansoprazole.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Vilazodone.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with fexofenadine.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Lomitapide.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Bortezomib.


The serum concentration of the active metabolites of Isavuconazonium can be increased when Isavuconazonium is used in combination with Idelalisib.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with imipramine.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with doxepin.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with lovastatin.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with tamoxifen.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with betaxolol.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with nicardipine.


The serum concentration of the active metabolites of Isavuconazonium can be increased when Isavuconazonium is used in combination with Darunavir.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with MEGESTROL ACETATE.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with clomipramine.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with ranitidine.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with nelfinavir.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with quetiapine.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with cyclosporin A.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with methylphenidate.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with cocaine.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Voriconazole.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with haloperidol.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with proguanil.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with nitrazepam.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with promazine.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with ALFENTANIL.


The serum concentration of the active metabolites of ifosfamide can be increased when ifosfamide is used in combination with Rifampicin.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with rosiglitazone.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with diltiazem.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with acebutolol.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Temsirolimus.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with codeine.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Sunitinib.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with IDARUBICIN.


The serum concentration of the active metabolites of prednisone can be increased when prednisone is used in combination with cyclosporin A.


The serum concentration of the active metabolites of Isavuconazonium can be increased when Isavuconazonium is used in combination with Atazanavir.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with miconazole.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with nifedipine.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with diclofenac.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with daunorubicin.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with clemastine.


The serum concentration of the active metabolites of clarithromycin can be increased when clarithromycin is used in combination with RIFAPENTINE.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Canagliflozin.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with spironolactone.


The serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with terbinafine.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Rolapitant.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with ELIGLUSTAT.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Artemether.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Flupentixol.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Afatinib.


The serum concentration of the active metabolites of clarithromycin can be increased when clarithromycin is used in combination with phenobarbital.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Escitalopram.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with imipramine.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with azithromycin.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with amitriptyline.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with rapamycin.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Levomepromazine.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with IVERMECTIN.


The serum concentration of the active metabolites of Roflumilast can be increased when Roflumilast is used in combination with fluvoxamine.


The serum concentration of the active metabolites of clarithromycin can be increased when clarithromycin is used in combination with Rifampicin.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with cimetidine.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with oxprenolol.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with TROLEANDOMYCIN.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with pentamidine.


The serum concentration of the active metabolites of azathioprine can be increased when azathioprine is used in combination with allopurinol.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with risperidone.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with fluvoxamine.


The serum concentration of the active metabolites of Isavuconazonium can be increased when Isavuconazonium is used in combination with amiodarone.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Reboxetine.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with clozapine.


The serum concentration of the active metabolites of carbamazepine can be increased when carbamazepine is used in combination with VALPROIC ACID.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with dolasetron.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with clotrimazole.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Tolvaptan.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Mepyramine.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with pravastatin.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with rivastigmine.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with PONATINIB.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with mitoxantrone.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with testosterone.


The serum concentration of the active metabolites of RIFABUTIN can be increased when RIFABUTIN is used in combination with SAQUINAVIR.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with DEXMEDETOMIDINE.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with ajmaline.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Enasidenib.


The serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Darunavir.


The serum concentration of the active metabolites of ifosfamide can be increased when ifosfamide is used in combination with RIFABUTIN.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Atazanavir.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with vinblastine.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with biperiden.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with lovastatin.


The serum concentration of the active metabolites of GLYCEROL PHENYLBUTYRATE can be increased when GLYCEROL PHENYLBUTYRATE is used in combination with probenecid.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Pibrentasvir.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with metoclopramide.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with clomipramine.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with fexofenadine.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Atomoxetine.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with methimazole.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with enalapril.


The serum concentration of the active metabolites of ifosfamide can be increased when ifosfamide is used in combination with pentobarbital.


The serum concentration of the active metabolites of Fosamprenavir can be increased when Fosamprenavir is used in combination with itraconazole.


The serum concentration of the active metabolites of ifosfamide can be increased when ifosfamide is used in combination with primidone.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with etoposide.


The serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Lopinavir.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Regorafenib.


The serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with cocaine.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with cisapride.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Glecaprevir.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with thioridazine.


The serum concentration of the active metabolites of clarithromycin can be increased when clarithromycin is used in combination with phenytoin.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with sulfaphenazole.


The serum concentration of the active metabolites of irinotecan can be increased when irinotecan is used in combination with gemfibrozil.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with albendazole.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with promethazine.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with nevirapine.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Mirabegron.


The serum concentration of the active metabolites of Fingolimod can be increased when Fingolimod is used in combination with ketoconazole.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with nifedipine.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with dextromethorphan.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with CARTEOLOL.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Sorafenib.


The serum concentration of the active metabolites of irinotecan can be increased when irinotecan is used in combination with Regorafenib.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with dextromethorphan.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with meprobamate.


The serum concentration of the active metabolites of aminophylline can be increased when aminophylline is used in combination with Febuxostat.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Darunavir.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Enasidenib.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with itraconazole.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with RANOLAZINE.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with thiothixene.


The serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with nelfinavir.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with diphenhydramine.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with histamine.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Atazanavir.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with metoprolol.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with methoxsalen.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Rifampicin.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with PRIMAQUINE.


The serum concentration of the active metabolites of Isavuconazonium can be increased when Isavuconazonium is used in combination with itraconazole.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with amiodarone.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Lercanidipine.


The serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Idelalisib.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with progesterone.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Dronabinol.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with lansoprazole.


The serum concentration of the active metabolites of CAPECITABINE can be increased when CAPECITABINE is used in combination with cimetidine.


The serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Telaprevir.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with ERGOTAMINE.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with amitriptyline.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with ketamine.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Vernakalant.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with flurazepam.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with terazosin.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with disulfiram.


The serum concentration of the active metabolites of CAPECITABINE can be increased when CAPECITABINE is used in combination with Gimeracil.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Isavuconazonium.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with simvastatin.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with omeprazole.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with epinastine.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Lapatinib.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with antipyrine.


The serum concentration of the active metabolites of clarithromycin can be increased when clarithromycin is used in combination with Bosentan.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with biperiden.


The serum concentration of the active metabolites of PROCAINAMIDE can be increased when PROCAINAMIDE is used in combination with trimethoprim.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with pergolide.


The serum concentration of the active metabolites of RIFABUTIN can be increased when RIFABUTIN is used in combination with Lopinavir.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with irbesartan.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with duloxetine.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with chloroquine.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with LEVOFLOXACIN.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with loperamide.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with CABAZITAXEL.


The serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with fluoxetine.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with propoxyphene.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with desipramine.


The serum concentration of the active metabolites of Isavuconazonium can be increased when Isavuconazonium is used in combination with Telithromycin.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with hydroxyurea.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with quinacrine.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Levalbuterol.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with ceritinib.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with chlorprothixene.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with quinidine.


The serum concentration of the active metabolites of 4-PHENYLBUTYRIC ACID can be increased when 4-PHENYLBUTYRIC ACID is used in combination with probenecid.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Aripiprazole.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with pantoprazole.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Lumacaftor.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with doxepin.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with granisetron.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with SAQUINAVIR.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with citalopram.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with mefloquine.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with midazolam.


The serum concentration of the active metabolites of oseltamivir can be increased when oseltamivir is used in combination with probenecid.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with selegiline.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Cinacalcet.


The serum concentration of the active metabolites of carbamazepine can be increased when carbamazepine is used in combination with loxapine.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with perphenazine.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with trimipramine.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Quinine.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with promethazine.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Cobicistat.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with amsacrine.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Voxilaprevir.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with ondansetron.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with diltiazem.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with nicotinic acid.


The serum concentration of the active metabolites of Temsirolimus can be increased when Temsirolimus is used in combination with Posaconazole.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with dextroamphetamine.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with sulconazole.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with CYPROTERONE ACETATE.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with maprotiline.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Nilotinib.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with ritonavir.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with mefloquine.


The serum concentration of the active metabolites of RIFABUTIN can be increased when RIFABUTIN is used in combination with indinavir.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Lorcaserin.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with RUCAPARIB.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Rotigotine.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with amantadine.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with oxymetholone.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with prazosin.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Ivacaftor.


The serum concentration of the active metabolites of clarithromycin can be increased when clarithromycin is used in combination with RIFABUTIN.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with propafenone.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with captopril.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with methazolamide.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with indomethacin.


The serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Delavirdine.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with fluoxetine.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Lopinavir.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with hydroxychloroquine.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with doxorubicin.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with propranolol.


The serum concentration of the active metabolites of leflunomide can be increased when leflunomide is used in combination with Rifampicin.


The serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with amiodarone.


The serum concentration of the active metabolites of azathioprine can be increased when azathioprine is used in combination with ribavirin.


The serum concentration of the active metabolites of Roflumilast can be increased when Roflumilast is used in combination with cimetidine.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with reserpine.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Nilotinib.


The serum concentration of the active metabolites of Propacetamol can be increased when Propacetamol is used in combination with probenecid.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Diacerein.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Boceprevir.


The serum concentration of the active metabolites of floxuridine can be increased when floxuridine is used in combination with Gimeracil.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with celecoxib.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with moclobemide.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with paroxetine.


The serum concentration of the active metabolites of ifosfamide can be increased when ifosfamide is used in combination with carbamazepine.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Tapentadol.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with dihydroergotamine.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with nicotinamide.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with SAQUINAVIR.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with probenecid.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Dothiepin.


The serum concentration of the active metabolites of Isavuconazonium can be increased when Isavuconazonium is used in combination with Boceprevir.


The serum concentration of the active metabolites of ifosfamide can be increased when ifosfamide is used in combination with phenytoin.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with nortriptyline.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Delavirdine.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with methadone.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Dexfenfluramine.


The serum concentration of the active metabolites of tegafur can be increased when tegafur is used in combination with metronidazole.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with ropinirole.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with ciprofloxacin.


The serum concentration of the active metabolites of RIFABUTIN can be increased when RIFABUTIN is used in combination with Atazanavir.


The serum concentration of the active metabolites of Isavuconazonium can be increased when Isavuconazonium is used in combination with SAQUINAVIR.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with vincristine.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Lopinavir.


The serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with indinavir.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with protriptyline.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with bicalutamide.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with vinblastine.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with chloroquine.


The serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Posaconazole.


The serum concentration of the active metabolites of carisoprodol can be increased when carisoprodol is used in combination with aspirin.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with clarithromycin.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Pazopanib.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with glycerol.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with propafenone.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Ospemifene.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Sorafenib.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with fluoxetine.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with indinavir.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with PERINDOPRIL.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with zafirlukast.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Abemaciclib.


The serum concentration of the active metabolites of Isavuconazonium can be increased when Isavuconazonium is used in combination with Cobicistat.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with chlorpheniramine.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with flecainide.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Ticagrelor.


The serum concentration of the active metabolites of primidone can be increased when primidone is used in combination with felbamate.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with VERAPAMIL.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Quinine.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Enzalutamide.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with 4-PHENYLBUTYRIC ACID.


The serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with bupropion.


The serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with ceritinib.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with tranylcypromine.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with azelastine.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with pyrimethamine.


The serum concentration of the active metabolites of Temsirolimus can be increased when Temsirolimus is used in combination with fluconazole.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with nefazodone.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Telithromycin.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Gramicidin D.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Trospium.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with sulfanilamide.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with actinomycin D.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with tripelennamine.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with clofazimine.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with lidocaine.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Posaconazole.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with fluconazole.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with RUCAPARIB.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with PERHEXILINE.


The serum concentration of the active metabolites of Isavuconazonium can be increased when Isavuconazonium is used in combination with nefazodone.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with naltrexone.


The serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Dothiepin.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with loratadine.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Telaprevir.


The serum concentration of the active metabolites of Isavuconazonium can be increased when Isavuconazonium is used in combination with Lopinavir.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with triprolidine.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with simvastatin.


The serum concentration of the active metabolites of 5-Fluorocytosine can be increased when 5-Fluorocytosine is used in combination with Gimeracil.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Desloratadine.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with omeprazole.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with caffeine.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with hydrocortisone.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with propranolol.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Asenapine.


The serum concentration of the active metabolites of Temsirolimus can be increased when Temsirolimus is used in combination with itraconazole.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with atorvastatin.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with buprenorphine.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with mianserin.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with praziquantel.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with NEOSTIGMINE.


The serum concentration of the active metabolites of RIFABUTIN can be increased when RIFABUTIN is used in combination with Elvitegravir.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with benzocaine.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with manidipine.


The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with dimethyl sulfoxide.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with sertraline.


The serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with thioridazine.


The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Bosutinib.


ceritinib may increase the hyperglycemic activities of Tixocortol.


ceritinib may increase the hyperglycemic activities of BECLOMETHASONE DIPROPIONATE.


ceritinib may increase the hyperglycemic activities of desoximetasone.


ceritinib may increase the hyperglycemic activities of medrysone.


ceritinib may increase the hyperglycemic activities of CLOCORTOLONE.


ceritinib may increase the hyperglycemic activities of equilin.


ceritinib may increase the hyperglycemic activities of FLUOCINOLONE ACETONIDE.


ceritinib may increase the hyperglycemic activities of Halobetasol.


ceritinib may increase the hyperglycemic activities of Clobetasone.


ceritinib may increase the hyperglycemic activities of formestane.


ceritinib may increase the hyperglycemic activities of PREDNICARBATE.


ceritinib may increase the hyperglycemic activities of CLOBETASOL PROPIONATE.


ceritinib may increase the hyperglycemic activities of loteprednol.


ceritinib may increase the hyperglycemic activities of RIMEXOLONE.


ceritinib may increase the hyperglycemic activities of Mometasone.


ceritinib may increase the hyperglycemic activities of flumethasone.


ceritinib may increase the hyperglycemic activities of DESONIDE.


ceritinib may increase the hyperglycemic activities of amcinonide.


ceritinib may increase the hyperglycemic activities of fludrocortisone.


ceritinib may increase the hyperglycemic activities of difluprednate.


ceritinib may increase the hyperglycemic activities of diflorasone.


ceritinib may increase the hyperglycemic activities of FLUOCORTOLONE.


ceritinib may increase the hyperglycemic activities of Fluprednidene.


ceritinib may increase the hyperglycemic activities of halcinonide.


ceritinib may increase the hyperglycemic activities of flurandrenolide.


ceritinib may increase the hyperglycemic activities of fluocinonide.


ceritinib may increase the hyperglycemic activities of betamethasone.


Pirlindole may increase the central nervous system depressant (CNS depressant) and hypertensive activities of SUFENTANIL.


isocarboxazid may increase the central nervous system depressant (CNS depressant) and hypertensive activities of ALFENTANIL.


Phenelzine may increase the central nervous system depressant (CNS depressant) and hypertensive activities of ALFENTANIL.


furazolidone may increase the central nervous system depressant (CNS depressant) and hypertensive activities of SUFENTANIL.


selegiline may increase the central nervous system depressant (CNS depressant) and hypertensive activities of ALFENTANIL.


moclobemide may increase the central nervous system depressant (CNS depressant) and hypertensive activities of REMIFENTANIL.


pargyline may increase the central nervous system depressant (CNS depressant) and hypertensive activities of ALFENTANIL.


moclobemide may increase the central nervous system depressant (CNS depressant) and hypertensive activities of SUFENTANIL.


furazolidone may increase the central nervous system depressant (CNS depressant) and hypertensive activities of REMIFENTANIL.


Pirlindole may increase the central nervous system depressant (CNS depressant) and hypertensive activities of REMIFENTANIL.


moclobemide may increase the central nervous system depressant (CNS depressant) and hypertensive activities of ALFENTANIL.


pargyline may increase the central nervous system depressant (CNS depressant) and hypertensive activities of REMIFENTANIL.


Toloxatone may increase the central nervous system depressant (CNS depressant) and hypertensive activities of REMIFENTANIL.


furazolidone may increase the central nervous system depressant (CNS depressant) and hypertensive activities of ALFENTANIL.


Toloxatone may increase the central nervous system depressant (CNS depressant) and hypertensive activities of SUFENTANIL.


rasagiline may increase the central nervous system depressant (CNS depressant) and hypertensive activities of ALFENTANIL.


pargyline may increase the central nervous system depressant (CNS depressant) and hypertensive activities of SUFENTANIL.


Pirlindole may increase the central nervous system depressant (CNS depressant) and hypertensive activities of ALFENTANIL.


Toloxatone may increase the central nervous system depressant (CNS depressant) and hypertensive activities of ALFENTANIL.


Imatinib may increase the hepatotoxic activities of Propacetamol.


quinidine may increase the hepatotoxic activities of phenobarbital.


6-Mercaptopurine may increase the hepatotoxic activities of doxorubicin.


amodiaquine may increase the hepatotoxic activities of efavirenz.


acetaminophen may increase the hepatotoxic activities of ethanol.


clonazepam may increase the hepatotoxic activities of Tetracosactide.


cyclosporin A may increase the hepatotoxic activities of OXANDROLONE.


Rifampicin may increase the hepatotoxic activities of pyrazinamide.


Mipomersen may increase the hepatotoxic activities of Lomitapide.


methotrexate may increase the hepatotoxic activities of Acitretin.


Bosentan may increase the hepatotoxic activities of glyburide.


zalcitabine may increase the hepatotoxic activities of ribavirin.


Propacetamol may increase the hepatotoxic activities of isoniazid.


Pazopanib may increase the hepatotoxic activities of simvastatin.


cyclosporin A may increase the hepatotoxic activities of NANDROLONE DECANOATE.


phenobarbital may increase the hepatotoxic activities of Tetracosactide.


abacavir may increase the hepatotoxic activities of ribavirin.


cyclosporin A may increase the hepatotoxic activities of danazol.


cyclosporin A may increase the hepatotoxic activities of testosterone propionate.


Mipomersen may increase the hepatotoxic activities of acetaminophen.


Propacetamol may increase the hepatotoxic activities of Mipomersen.


Trabectedin may increase the hepatotoxic activities of ethanol.


Mipomersen may increase the hepatotoxic activities of Isotretinoin.


lamivudine may increase the hepatotoxic activities of ribavirin.


Mipomersen may increase the hepatotoxic activities of doxycycline.


primidone may increase the hepatotoxic activities of Tetracosactide.


cyclosporin A may increase the hepatotoxic activities of methyltestosterone.


Propacetamol may increase the hepatotoxic activities of Sorafenib.


Pazopanib may increase the hepatotoxic activities of Pitavastatin.


Mipomersen may increase the hepatotoxic activities of chlortetracycline.


methotrexate may increase the hepatotoxic activities of sulfasalazine.


cyclosporin A may increase the hepatotoxic activities of stanozolol.


methotrexate may increase the hepatotoxic activities of Alitretinoin.


Emtricitabine may increase the hepatotoxic activities of ribavirin.


Propacetamol may increase the hepatotoxic activities of Dasatinib.


Pazopanib may increase the hepatotoxic activities of Rosuvastatin.


phenytoin may increase the hepatotoxic activities of Tetracosactide.


Dasatinib may increase the hepatotoxic activities of acetaminophen.


Pazopanib may increase the hepatotoxic activities of fluvastatin.


stavudine may increase the hepatotoxic activities of ribavirin.


cyclosporin A may increase the hepatotoxic activities of testosterone.


isoniazid may increase the hepatotoxic activities of RIFABUTIN.


methotrexate may increase the hepatotoxic activities of Mipomersen.


Pazopanib may increase the hepatotoxic activities of Coenzyme Q10.


nitrazepam may increase the hepatotoxic activities of Tetracosactide.


VALPROIC ACID may increase the hepatotoxic activities of Tetracosactide.


cyclosporin A may increase the hepatotoxic activities of fluoxymesterone.


Mipomersen may increase the hepatotoxic activities of minocycline.


Entecavir may increase the hepatotoxic activities of ribavirin.


Mipomersen may increase the hepatotoxic activities of amiodarone.


Mipomersen may increase the hepatotoxic activities of ethanol.


Mipomersen may increase the hepatotoxic activities of tamoxifen.


cyclosporin A may increase the hepatotoxic activities of oxymetholone.


isoniazid may increase the hepatotoxic activities of Rifaximin.


isoniazid may increase the hepatotoxic activities of RIFAPENTINE.


Imatinib may increase the hepatotoxic activities of acetaminophen.


Mipomersen may increase the hepatotoxic activities of demeclocycline.


diazepam may increase the hepatotoxic activities of Tetracosactide.


Pazopanib may increase the hepatotoxic activities of lovastatin.


cyclophosphamide may increase the hepatotoxic activities of azathioprine.


Sorafenib may increase the hepatotoxic activities of acetaminophen.


isoniazid may increase the hepatotoxic activities of Rifampicin.


Bedaquiline may increase the hepatotoxic activities of ethanol.


Lomitapide may increase the hepatotoxic activities of ethanol.


tranexamic acid may increase the thrombogenic activities of dienestrol.


Lenalidomide may increase the thrombogenic activities of dexamethasone.


GESTODENE may increase the thrombogenic activities of tranexamic acid.


thalidomide may increase the thrombogenic activities of NORGESTIMATE.


ethinyl estradiol may increase the thrombogenic activities of etodolac.


mestranol may increase the thrombogenic activities of Etoricoxib.


estrone may increase the thrombogenic activities of celecoxib.


ethinyl estradiol may increase the thrombogenic activities of Lumiracoxib.


thalidomide may increase the thrombogenic activities of ETONOGESTREL.


QUINESTROL may increase the thrombogenic activities of nabumetone.


NORGESTIMATE may increase the thrombogenic activities of tranexamic acid.


tibolone may increase the thrombogenic activities of Etoricoxib.


Lenalidomide may increase the thrombogenic activities of tibolone.


6-aminohexanoic acid may increase the thrombogenic activities of tretinoin.


mestranol may increase the thrombogenic activities of etodolac.


Lenalidomide may increase the thrombogenic activities of QUINESTROL.


Lenalidomide may increase the thrombogenic activities of estriol.


mestranol may increase the thrombogenic activities of nabumetone.


thalidomide may increase the thrombogenic activities of dienestrol.


diethylstilbestrol may increase the thrombogenic activities of Etoricoxib.


Medroxyprogesterone acetate may increase the thrombogenic activities of tranexamic acid.


diethylstilbestrol may increase the thrombogenic activities of etodolac.


thalidomide may increase the thrombogenic activities of estramustine.


thalidomide may increase the thrombogenic activities of estradiol.


thalidomide may increase the thrombogenic activities of ethinyl estradiol.


thalidomide may increase the thrombogenic activities of Drospirenone.


tranexamic acid may increase the thrombogenic activities of ethinyl estradiol.


thalidomide may increase the thrombogenic activities of DESOGESTREL.


diethylstilbestrol may increase the thrombogenic activities of nabumetone.


diethylstilbestrol may increase the thrombogenic activities of celecoxib.


dienestrol may increase the thrombogenic activities of Etoricoxib.


estriol may increase the thrombogenic activities of Etoricoxib.


mestranol may increase the thrombogenic activities of Lumiracoxib.


tranexamic acid may increase the thrombogenic activities of estradiol.


diethylstilbestrol may increase the thrombogenic activities of Lumiracoxib.


estriol may increase the thrombogenic activities of nabumetone.


estradiol may increase the thrombogenic activities of Etoricoxib.


tranexamic acid may increase the thrombogenic activities of diethylstilbestrol.


thalidomide may increase the thrombogenic activities of Dienogest.


dienestrol may increase the thrombogenic activities of nabumetone.


thalidomide may increase the thrombogenic activities of norgestrel.


estradiol may increase the thrombogenic activities of etodolac.


dienestrol may increase the thrombogenic activities of celecoxib.


estriol may increase the thrombogenic activities of celecoxib.


thalidomide may increase the thrombogenic activities of estrone.


QUINESTROL may increase the thrombogenic activities of Etoricoxib.


estradiol may increase the thrombogenic activities of nabumetone.


tranexamic acid may increase the thrombogenic activities of Estrone sulfate.


thalidomide may increase the thrombogenic activities of diethylstilbestrol.


mestranol may increase the thrombogenic activities of celecoxib.


norgestrel may increase the thrombogenic activities of tranexamic acid.


Lenalidomide may increase the thrombogenic activities of mestranol.


ETHYNODIOL DIACETATE may increase the thrombogenic activities of tranexamic acid.


estrone may increase the thrombogenic activities of etodolac.


estrone may increase the thrombogenic activities of Etoricoxib.


ethinyl estradiol may increase the thrombogenic activities of Etoricoxib.


Lenalidomide may increase the thrombogenic activities of ethinyl estradiol.


QUINESTROL may increase the thrombogenic activities of etodolac.


phytonadione may increase the thrombogenic activities of tretinoin.


estradiol may increase the thrombogenic activities of Lumiracoxib.


tibolone may increase the thrombogenic activities of Lumiracoxib.


thalidomide may increase the thrombogenic activities of Norelgestromin.


estriol may increase the thrombogenic activities of Lumiracoxib.


tibolone may increase the thrombogenic activities of etodolac.


Norelgestromin may increase the thrombogenic activities of tranexamic acid.


ethinyl estradiol may increase the thrombogenic activities of nabumetone.


thalidomide may increase the thrombogenic activities of ETHYNODIOL DIACETATE.


tranexamic acid may increase the thrombogenic activities of estramustine.


ethinyl estradiol may increase the thrombogenic activities of celecoxib.


dienestrol may increase the thrombogenic activities of etodolac.


estriol may increase the thrombogenic activities of etodolac.


dienestrol may increase the thrombogenic activities of Lumiracoxib.


thalidomide may increase the thrombogenic activities of QUINESTROL.


thalidomide may increase the thrombogenic activities of Estrone sulfate.


estradiol may increase the thrombogenic activities of celecoxib.


thalidomide may increase the thrombogenic activities of estriol.


Lenalidomide may increase the thrombogenic activities of diethylstilbestrol.


QUINESTROL may increase the thrombogenic activities of celecoxib.


thalidomide may increase the thrombogenic activities of mestranol.


tibolone may increase the thrombogenic activities of celecoxib.


Dienogest may increase the thrombogenic activities of tranexamic acid.


tibolone may increase the thrombogenic activities of nabumetone.


tranexamic acid may increase the thrombogenic activities of tretinoin.


QUINESTROL may increase the thrombogenic activities of Lumiracoxib.


Lenalidomide may increase the thrombogenic activities of estradiol.


Levonorgestrel may increase the thrombogenic activities of tranexamic acid.


DESOGESTREL may increase the thrombogenic activities of tranexamic acid.


thalidomide may increase the thrombogenic activities of tibolone.


thalidomide may increase the thrombogenic activities of Medroxyprogesterone acetate.


menadione may increase the thrombogenic activities of tretinoin.


ETONOGESTREL may increase the thrombogenic activities of tranexamic acid.


Lenalidomide may increase the thrombogenic activities of dienestrol.


estrone may increase the thrombogenic activities of Lumiracoxib.


thalidomide may increase the thrombogenic activities of GESTODENE.


estrone may increase the thrombogenic activities of nabumetone.


thalidomide may increase the thrombogenic activities of Levonorgestrel.


Drospirenone may increase the thrombogenic activities of tranexamic acid.


tranexamic acid may increase the thrombogenic activities of mestranol.


Lenalidomide may increase the thrombogenic activities of estrone.


mequitazine may increase the arrhythmogenic activities of Asenapine.


deslanoside may increase the arrhythmogenic activities of calcium lactate.


Dronedarone may increase the arrhythmogenic activities of Fingolimod.


digitoxin may increase the arrhythmogenic activities of GALLAMINE TRIETHIODIDE.


digitoxin may increase the arrhythmogenic activities of CALCIUM GLUCONATE.


halothane may increase the arrhythmogenic activities of Ephedrine.


acetyldigitoxin may increase the arrhythmogenic activities of Paricalcitol.


dopamine may increase the arrhythmogenic activities of sevoflurane.


astemizole may increase the arrhythmogenic activities of Delavirdine.


digoxin may increase the arrhythmogenic activities of GALLAMINE TRIETHIODIDE.


disopyramide may increase the arrhythmogenic activities of Fingolimod.


TRICHLOROETHYLENE may increase the arrhythmogenic activities of Ephedrine.


mequitazine may increase the arrhythmogenic activities of amisulpride.


dopamine may increase the arrhythmogenic activities of enflurane.


digoxin may increase the arrhythmogenic activities of ergocalciferol.


propafenone may increase the arrhythmogenic activities of SAQUINAVIR.


deslanoside may increase the arrhythmogenic activities of Doxercalciferol.


isoproterenol may increase the arrhythmogenic activities of TRICHLOROETHYLENE.


clomipramine may increase the arrhythmogenic activities of Liotrix.


ciprofloxacin may increase the arrhythmogenic activities of losartan.


dopamine may increase the arrhythmogenic activities of halothane.


epinephrine may increase the arrhythmogenic activities of sevoflurane.


mequitazine may increase the arrhythmogenic activities of sulpiride.


desipramine may increase the arrhythmogenic activities of Liotrix.


Ibutilide may increase the arrhythmogenic activities of Fingolimod.


deslanoside may increase the arrhythmogenic activities of dihydrotachysterol.


digitoxin may increase the arrhythmogenic activities of calcium lactate.


mequitazine may increase the arrhythmogenic activities of Pipamperone.


deslanoside may increase the arrhythmogenic activities of succinylcholine.


deslanoside may increase the arrhythmogenic activities of Glubionate calcium.


Tianeptine may increase the arrhythmogenic activities of L-thyroxine.


acetyldigitoxin may increase the arrhythmogenic activities of Calcifediol.


digitoxin may increase the arrhythmogenic activities of tubocurarine.


Panobinostat may increase the arrhythmogenic activities of ondansetron.


norepinephrine may increase the arrhythmogenic activities of DESFLURANE.


mequitazine may increase the arrhythmogenic activities of droperidol.


mequitazine may increase the arrhythmogenic activities of periciazine.


mequitazine may increase the arrhythmogenic activities of lithium ion.


ouabain may increase the arrhythmogenic activities of Calcium citrate.


ciprofloxacin may increase the arrhythmogenic activities of PERINDOPRIL.


mequitazine may increase the arrhythmogenic activities of risperidone.


mequitazine may increase the arrhythmogenic activities of MELPERONE.


acetyldigitoxin may increase the arrhythmogenic activities of Mivacurium.


deslanoside may increase the arrhythmogenic activities of Mivacurium.


mequitazine may increase the arrhythmogenic activities of pentamidine.


Ivabradine may increase the arrhythmogenic activities of indapamide.


digoxin may increase the arrhythmogenic activities of decamethonium.


mirtazapine may increase the arrhythmogenic activities of liothyronine.


cyclobenzaprine may increase the arrhythmogenic activities of liothyronine.


ouabain may increase the arrhythmogenic activities of decamethonium.


isoflurane may increase the arrhythmogenic activities of Ephedrine.


mirtazapine may increase the arrhythmogenic activities of L-thyroxine.


acetyldigitoxin may increase the arrhythmogenic activities of Doxacurium.


digitoxin may increase the arrhythmogenic activities of Atracurium besylate.


mequitazine may increase the arrhythmogenic activities of perphenazine.


digitoxin may increase the arrhythmogenic activities of Doxercalciferol.


mequitazine may increase the arrhythmogenic activities of zotepine.


mequitazine may increase the arrhythmogenic activities of tiapride.


ciprofloxacin may increase the arrhythmogenic activities of captopril.


deslanoside may increase the arrhythmogenic activities of Doxacurium.


clomipramine may increase the arrhythmogenic activities of L-thyroxine.


digoxin may increase the arrhythmogenic activities of Calcium phosphate.


digoxin may increase the arrhythmogenic activities of Glubionate calcium.


acetyldigitoxin may increase the arrhythmogenic activities of Rocuronium.


ouabain may increase the arrhythmogenic activities of Calcifediol.


imipramine may increase the arrhythmogenic activities of L-thyroxine.


mequitazine may increase the arrhythmogenic activities of Lurasidone.


formoterol may increase the arrhythmogenic activities of methoxyflurane.


formoterol may increase the arrhythmogenic activities of enflurane.


acetyldigitoxin may increase the arrhythmogenic activities of Cisatracurium.


dopamine may increase the arrhythmogenic activities of isoflurane.


DESFLURANE may increase the arrhythmogenic activities of Ephedrine.


ciprofloxacin may increase the arrhythmogenic activities of cilazapril.


mequitazine may increase the arrhythmogenic activities of pimozide.


Dothiepin may increase the arrhythmogenic activities of liothyronine.


ciprofloxacin may increase the arrhythmogenic activities of Spirapril.


ciprofloxacin may increase the arrhythmogenic activities of TASOSARTAN.


digitoxin may increase the arrhythmogenic activities of Calcium acetate.


ouabain may increase the arrhythmogenic activities of Paricalcitol.


digitoxin may increase the arrhythmogenic activities of dihydrotachysterol.


acetyldigitoxin may increase the arrhythmogenic activities of Calcium phosphate.


norepinephrine may increase the arrhythmogenic activities of nitrous oxide.


mequitazine may increase the arrhythmogenic activities of thioridazine.


Panobinostat may increase the arrhythmogenic activities of dolasetron.


deslanoside may increase the arrhythmogenic activities of Calcifediol.


formoterol may increase the arrhythmogenic activities of halothane.


mequitazine may increase the arrhythmogenic activities of Perospirone.


Ivabradine may increase the arrhythmogenic activities of furosemide.


ouabain may increase the arrhythmogenic activities of CALCIUM GLUCONATE.


acetyldigitoxin may increase the arrhythmogenic activities of dihydrotachysterol.


mequitazine may increase the arrhythmogenic activities of quetiapine.


nortriptyline may increase the arrhythmogenic activities of liothyronine.


ouabain may increase the arrhythmogenic activities of tubocurarine.


digoxin may increase the arrhythmogenic activities of Calcium citrate.


digoxin may increase the arrhythmogenic activities of PYRANTEL.


Ivabradine may increase the arrhythmogenic activities of hydrochlorothiazide.


ouabain may increase the arrhythmogenic activities of Calcium phosphate.


thioridazine may increase the arrhythmogenic activities of chlorpheniramine.


ouabain may increase the arrhythmogenic activities of Vecuronium.


acetyldigitoxin may increase the arrhythmogenic activities of Doxercalciferol.


ouabain may increase the arrhythmogenic activities of METOCURINE.


ouabain may increase the arrhythmogenic activities of pancuronium.


digitoxin may increase the arrhythmogenic activities of Calcium phosphate.


digoxin may increase the arrhythmogenic activities of Cisatracurium.


amoxapine may increase the arrhythmogenic activities of L-thyroxine.


amitriptyline may increase the arrhythmogenic activities of Liotrix.


formoterol may increase the arrhythmogenic activities of DESFLURANE.


ciprofloxacin may increase the arrhythmogenic activities of Enalaprilat.


mequitazine may increase the arrhythmogenic activities of loxapine.


mequitazine may increase the arrhythmogenic activities of Remoxipride.


mequitazine may increase the arrhythmogenic activities of SERTINDOLE.


nortriptyline may increase the arrhythmogenic activities of Liotrix.


ouabain may increase the arrhythmogenic activities of GALLAMINE TRIETHIODIDE.


acetyldigitoxin may increase the arrhythmogenic activities of Calcium acetate.


ouabain may increase the arrhythmogenic activities of Doxercalciferol.


enflurane may increase the arrhythmogenic activities of Ephedrine.


mequitazine may increase the arrhythmogenic activities of Cyamemazine.


acetyldigitoxin may increase the arrhythmogenic activities of ergocalciferol.


ouabain may increase the arrhythmogenic activities of Calcium acetate.


digitoxin may increase the arrhythmogenic activities of Rocuronium.


mequitazine may increase the arrhythmogenic activities of chlorprothixene.


protriptyline may increase the arrhythmogenic activities of liothyronine.


Dofetilide may increase the arrhythmogenic activities of Fingolimod.


deslanoside may increase the arrhythmogenic activities of tubocurarine.


digitoxin may increase the arrhythmogenic activities of succinylcholine.


mequitazine may increase the arrhythmogenic activities of MOLINDONE.


mequitazine may increase the arrhythmogenic activities of Paliperidone.


acetyldigitoxin may increase the arrhythmogenic activities of Calcium citrate.


epinephrine may increase the arrhythmogenic activities of enflurane.


digoxin may increase the arrhythmogenic activities of Doxercalciferol.


mequitazine may increase the arrhythmogenic activities of Aceprometazine.


trimipramine may increase the arrhythmogenic activities of L-thyroxine.


norepinephrine may increase the arrhythmogenic activities of halothane.


digoxin may increase the arrhythmogenic activities of PIPECURONIUM.


digoxin may increase the arrhythmogenic activities of succinylcholine.


digoxin may increase the arrhythmogenic activities of METOCURINE.


digoxin may increase the arrhythmogenic activities of pancuronium.


deslanoside may increase the arrhythmogenic activities of Calcium citrate.


digitoxin may increase the arrhythmogenic activities of Doxacurium.


lidocaine may increase the arrhythmogenic activities of disopyramide.


formoterol may increase the arrhythmogenic activities of sevoflurane.


norepinephrine may increase the arrhythmogenic activities of methoxyflurane.


mequitazine may increase the arrhythmogenic activities of Fencamfamin.


Ivabradine may increase the arrhythmogenic activities of trichlormethiazide.


cyclobenzaprine may increase the arrhythmogenic activities of L-thyroxine.


isoproterenol may increase the arrhythmogenic activities of enflurane.


isoproterenol may increase the arrhythmogenic activities of halothane.


dopamine may increase the arrhythmogenic activities of nitrous oxide.


deslanoside may increase the arrhythmogenic activities of decamethonium.


dopamine may increase the arrhythmogenic activities of DESFLURANE.


Ivabradine may increase the arrhythmogenic activities of Torasemide.


mequitazine may increase the arrhythmogenic activities of clozapine.


Ibutilide may increase the arrhythmogenic activities of lidocaine.


ciprofloxacin may increase the arrhythmogenic activities of AZILSARTAN MEDOXOMIL.


ciprofloxacin may increase the arrhythmogenic activities of rescinnamine.


Ivabradine may increase the arrhythmogenic activities of hydroflumethiazide.


deslanoside may increase the arrhythmogenic activities of Paricalcitol.


deslanoside may increase the arrhythmogenic activities of Cisatracurium.


nitrous oxide may increase the arrhythmogenic activities of Ephedrine.


digitoxin may increase the arrhythmogenic activities of Calcifediol.


quinidine may increase the arrhythmogenic activities of propafenone.


acetyldigitoxin may increase the arrhythmogenic activities of Atracurium besylate.


deslanoside may increase the arrhythmogenic activities of Calcium acetate.


mequitazine may increase the arrhythmogenic activities of moxifloxacin.


acetyldigitoxin may increase the arrhythmogenic activities of Cisatracurium.


imipramine may increase the arrhythmogenic activities of Liotrix.


deslanoside may increase the arrhythmogenic activities of CALCIUM GLUCONATE.


mequitazine may increase the arrhythmogenic activities of BREXPIPRAZOLE.


isoproterenol may increase the arrhythmogenic activities of isoflurane.


digoxin may increase the arrhythmogenic activities of CALCIUM CHLORIDE.


mequitazine may increase the arrhythmogenic activities of FLUPHENAZINE.


digitoxin may increase the arrhythmogenic activities of Cisatracurium.


lidocaine may increase the arrhythmogenic activities of SAQUINAVIR.


digitoxin may increase the arrhythmogenic activities of CALCIUM CHLORIDE.


Ivabradine may increase the arrhythmogenic activities of chlorthalidone.


digoxin may increase the arrhythmogenic activities of Vecuronium.


acetyldigitoxin may increase the arrhythmogenic activities of succinylcholine.


deslanoside may increase the arrhythmogenic activities of Calcium phosphate.


isoproterenol may increase the arrhythmogenic activities of nitrous oxide.


acetyldigitoxin may increase the arrhythmogenic activities of Glubionate calcium.


Panobinostat may increase the arrhythmogenic activities of granisetron.


acetyldigitoxin may increase the arrhythmogenic activities of calcium lactate.


mequitazine may increase the arrhythmogenic activities of Aripiprazole.


Dofetilide may increase the arrhythmogenic activities of propafenone.


mequitazine may increase the arrhythmogenic activities of thiothixene.


mequitazine may increase the arrhythmogenic activities of Thioproperazine.


mequitazine may increase the arrhythmogenic activities of Pipotiazine.


acetyldigitoxin may increase the arrhythmogenic activities of CALCIUM CHLORIDE.


mequitazine may increase the arrhythmogenic activities of Zuclopenthixol.


disopyramide may increase the arrhythmogenic activities of propafenone.


acetyldigitoxin may increase the arrhythmogenic activities of decamethonium.


norepinephrine may increase the arrhythmogenic activities of isoflurane.


doxepin may increase the arrhythmogenic activities of L-thyroxine.


digoxin may increase the arrhythmogenic activities of Cisatracurium.


ciprofloxacin may increase the arrhythmogenic activities of Olmesartan.


ciprofloxacin may increase the arrhythmogenic activities of valsartan.


ciprofloxacin may increase the arrhythmogenic activities of ramipril.


deslanoside may increase the arrhythmogenic activities of GALLAMINE TRIETHIODIDE.


PROCAINAMIDE may increase the arrhythmogenic activities of Fingolimod.


isoproterenol may increase the arrhythmogenic activities of methoxyflurane.


deslanoside may increase the arrhythmogenic activities of PIPECURONIUM.


deslanoside may increase the arrhythmogenic activities of Vecuronium.


mequitazine may increase the arrhythmogenic activities of mesoridazine.


isoproterenol may increase the arrhythmogenic activities of DESFLURANE.


deslanoside may increase the arrhythmogenic activities of METOCURINE.


deslanoside may increase the arrhythmogenic activities of pancuronium.


ajmaline may increase the arrhythmogenic activities of Fingolimod.


digoxin may increase the arrhythmogenic activities of Calcifediol.


ciprofloxacin may increase the arrhythmogenic activities of Eprosartan.


amoxapine may increase the arrhythmogenic activities of Liotrix.


ouabain may increase the arrhythmogenic activities of Atracurium besylate.


mequitazine may increase the arrhythmogenic activities of prochlorperazine.


ouabain may increase the arrhythmogenic activities of calcium lactate.


norepinephrine may increase the arrhythmogenic activities of sevoflurane.


Tianeptine may increase the arrhythmogenic activities of liothyronine.


quinidine may increase the arrhythmogenic activities of Fingolimod.


mequitazine may increase the arrhythmogenic activities of ACETOPHENAZINE.


norepinephrine may increase the arrhythmogenic activities of enflurane.


mirtazapine may increase the arrhythmogenic activities of Liotrix.


isoproterenol may increase the arrhythmogenic activities of sevoflurane.


mequitazine may increase the arrhythmogenic activities of Cariprazine.


dopamine may increase the arrhythmogenic activities of TRICHLOROETHYLENE.


cisapride may increase the arrhythmogenic activities of protriptyline.


doxepin may increase the arrhythmogenic activities of liothyronine.


mequitazine may increase the arrhythmogenic activities of Ziprasidone.


formoterol may increase the arrhythmogenic activities of TRICHLOROETHYLENE.


Dofetilide may increase the arrhythmogenic activities of SAQUINAVIR.


Dothiepin may increase the arrhythmogenic activities of Liotrix.


acetyldigitoxin may increase the arrhythmogenic activities of pancuronium.


acetyldigitoxin may increase the arrhythmogenic activities of METOCURINE.


acetyldigitoxin may increase the arrhythmogenic activities of Vecuronium.


acetyldigitoxin may increase the arrhythmogenic activities of PIPECURONIUM.


mequitazine may increase the arrhythmogenic activities of haloperidol.


deslanoside may increase the arrhythmogenic activities of Atracurium besylate.


digoxin may increase the arrhythmogenic activities of Doxacurium.


ouabain may increase the arrhythmogenic activities of PYRANTEL.


ouabain may increase the arrhythmogenic activities of Cisatracurium.


Dothiepin may increase the arrhythmogenic activities of L-thyroxine.


digitoxin may increase the arrhythmogenic activities of Mivacurium.


protriptyline may increase the arrhythmogenic activities of Liotrix.


ouabain may increase the arrhythmogenic activities of CALCIUM CHLORIDE.


nortriptyline may increase the arrhythmogenic activities of L-thyroxine.


mequitazine may increase the arrhythmogenic activities of dolasetron.


Ivabradine may increase the arrhythmogenic activities of BENDROFLUMETHIAZIDE.


digoxin may increase the arrhythmogenic activities of Mivacurium.


digitoxin may increase the arrhythmogenic activities of PYRANTEL.


doxepin may increase the arrhythmogenic activities of Liotrix.


digitoxin may increase the arrhythmogenic activities of Calcium citrate.


flecainide may increase the arrhythmogenic activities of SAQUINAVIR.


trimipramine may increase the arrhythmogenic activities of Liotrix.


mequitazine may increase the arrhythmogenic activities of Flupentixol.


digoxin may increase the arrhythmogenic activities of calcium lactate.


formoterol may increase the arrhythmogenic activities of nitrous oxide.


Dronedarone may increase the arrhythmogenic activities of lidocaine.


amiodarone may increase the arrhythmogenic activities of Fingolimod.


mequitazine may increase the arrhythmogenic activities of Levomepromazine.


clomipramine may increase the arrhythmogenic activities of liothyronine.


digitoxin may increase the arrhythmogenic activities of ergocalciferol.


digitoxin may increase the arrhythmogenic activities of PIPECURONIUM.


mequitazine may increase the arrhythmogenic activities of reserpine.


digitoxin may increase the arrhythmogenic activities of Cisatracurium.


ciprofloxacin may increase the arrhythmogenic activities of Sacubitril.


ciprofloxacin may increase the arrhythmogenic activities of Telmisartan.


digoxin may increase the arrhythmogenic activities of dihydrotachysterol.


deslanoside may increase the arrhythmogenic activities of CALCIUM CHLORIDE.


digitoxin may increase the arrhythmogenic activities of METOCURINE.


epinephrine may increase the arrhythmogenic activities of methoxyflurane.


amoxapine may increase the arrhythmogenic activities of liothyronine.


epinephrine may increase the arrhythmogenic activities of DESFLURANE.


ciprofloxacin may increase the arrhythmogenic activities of benazepril.


digoxin may increase the arrhythmogenic activities of Calcium acetate.


Ivabradine may increase the arrhythmogenic activities of ETHACRYNIC ACID.


protriptyline may increase the arrhythmogenic activities of L-thyroxine.


digitoxin may increase the arrhythmogenic activities of Paricalcitol.


Dofetilide may increase the arrhythmogenic activities of lidocaine.


epinephrine may increase the arrhythmogenic activities of isoflurane.


amitriptyline may increase the arrhythmogenic activities of L-thyroxine.


Ivabradine may increase the arrhythmogenic activities of chlorothiazide.


Ivabradine may increase the arrhythmogenic activities of bumetanide.


SAQUINAVIR may increase the arrhythmogenic activities of bepridil.


norepinephrine may increase the arrhythmogenic activities of TRICHLOROETHYLENE.


mequitazine may increase the arrhythmogenic activities of trifluoperazine.


Ivabradine may increase the arrhythmogenic activities of methyclothiazide.


Ivabradine may increase the arrhythmogenic activities of QUINETHAZONE.


Ivabradine may increase the arrhythmogenic activities of polythiazide.


ciprofloxacin may increase the arrhythmogenic activities of Candesartan cilexetil.


ouabain may increase the arrhythmogenic activities of Glubionate calcium.


formoterol may increase the arrhythmogenic activities of isoflurane.


ciprofloxacin may increase the arrhythmogenic activities of fosinopril.


digoxin may increase the arrhythmogenic activities of CALCIUM GLUCONATE.


epinephrine may increase the arrhythmogenic activities of TRICHLOROETHYLENE.


ouabain may increase the arrhythmogenic activities of PIPECURONIUM.


epinephrine may increase the arrhythmogenic activities of nitrous oxide.


mequitazine may increase the arrhythmogenic activities of ondansetron.


digitoxin may increase the arrhythmogenic activities of Glubionate calcium.


ciprofloxacin may increase the arrhythmogenic activities of lisinopril.


ouabain may increase the arrhythmogenic activities of Rocuronium.


Tianeptine may increase the arrhythmogenic activities of Liotrix.


ouabain may increase the arrhythmogenic activities of Mivacurium.


deslanoside may increase the arrhythmogenic activities of PYRANTEL.


mequitazine may increase the arrhythmogenic activities of Fluspirilene.


ouabain may increase the arrhythmogenic activities of Doxacurium.


ciprofloxacin may increase the arrhythmogenic activities of irbesartan.


ciprofloxacin may increase the arrhythmogenic activities of quinapril.


digoxin may increase the arrhythmogenic activities of Atracurium besylate.


ajmaline may increase the arrhythmogenic activities of propafenone.


desipramine may increase the arrhythmogenic activities of L-thyroxine.


methoxyflurane may increase the arrhythmogenic activities of Ephedrine.


acetyldigitoxin may increase the arrhythmogenic activities of PYRANTEL.


acetyldigitoxin may increase the arrhythmogenic activities of GALLAMINE TRIETHIODIDE.


mequitazine may increase the arrhythmogenic activities of methadone.


mequitazine may increase the arrhythmogenic activities of olanzapine.


ouabain may increase the arrhythmogenic activities of ergocalciferol.


sevoflurane may increase the arrhythmogenic activities of Ephedrine.


amitriptyline may increase the arrhythmogenic activities of liothyronine.


digoxin may increase the arrhythmogenic activities of Rocuronium.


Ibutilide may increase the arrhythmogenic activities of propafenone.


digitoxin may increase the arrhythmogenic activities of decamethonium.


deslanoside may increase the arrhythmogenic activities of Rocuronium.


ciprofloxacin may increase the arrhythmogenic activities of spironolactone.


imipramine may increase the arrhythmogenic activities of liothyronine.


mequitazine may increase the arrhythmogenic activities of triflupromazine.


acetyldigitoxin may increase the arrhythmogenic activities of CALCIUM GLUCONATE.


mequitazine may increase the arrhythmogenic activities of erythromycin.


PROCAINAMIDE may increase the arrhythmogenic activities of propafenone.


digitoxin may increase the arrhythmogenic activities of Vecuronium.


epinephrine may increase the arrhythmogenic activities of halothane.


digitoxin may increase the arrhythmogenic activities of pancuronium.